Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

announced in August, the increasing uptake of Vidaza for European named patient and compassionate use that fueled Vidaza sales growth during the year, as well as significant progress in clinical research across our product portfolio, including the initiation of clinical studies for Amrubicin, MGCD0103 and oral Azacitidine."

2007 Financial Highlights

Pharmion reported a net loss of $(63.9) million, or $(1.81) per share for the year ended December 31, 2007, and a net loss of $(27.5) million, or $(0.74) for the fourth quarter of 2007. These losses include $8.6 million of expenses incurred in connection with the Company's pending acquisition by Celgene Corporation announced in November 2007 as well as charges for stock compensation expense of $5.7 million for 2007 and $1.5 million for the fourth quarter of 2007. In addition, the losses for year ended December 31, 2007 include a charge of $8 million for a milestone payment triggered by the acceptance of Pharmion's marketing authorization application (MAA) for Satraplatin for the treatment of second-line hormone-refractory prostate cancer by the European Medicines Agency (EMEA).

Research and development expenses totaled $102.4 million and $30.4 million for the full year and fourth quarter of 2007, respectively. These amounts compare to research and development expenses for the full year and fourth quarter of 2006 of $70.1 million and $20.0 million, respectively. The increase in R&D spending for 2007 was expected and was due primarily to development expenses incurred for the initiation of Phase 2 and 3 studies in small cell lung cancer (SCLC) for Amrubicin, the initiation of Phase 1 and 2 studies in solid tumors and chronic lymphocytic leukemia (CLL) for MGCD0103, the opening of centers and enrolling of patients in the dose escalation study for oral Azacitidine and the initiation of our research collaboration program with MethylGene Inc. targeting sirtuin inhibitors.

Selling, general and admini
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... Dec. 22, 2014  Alternative Energy & Environmental ... has signed a letter of intent to acquire ... and patented a nanotechnology-based development platform used to ... enable rapid on-site collection and testing to identify ... issues in an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... 8, 2011 Golden Seeds, an investment firm dedicated ... empowerment of women entrepreneurs, announced today that it has ... in Pittsburgh, Pennsylvania to support the growing number of ... state-wide in Pennsylvania.  Since its first Pittsburgh investment in ...
... 8, 2011 Reportlinker.com announces that a new ... catalogue: Global High Throughput ... http://www.reportlinker.com/p0611062/Global-High-Throughput-Screening-HTS-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc This report analyzes ... (HTS) in US$ Million. The report provides ...
... September 7, 2011 Scientists at The Scripps Research Institute ... hydrocephalus, one of the most common neurological disorders of childhood ... newborn children. The research appears in the September 7, ... Hydrocephalus, which involves excess buildup of cerebrospinal fluid in ...
Cached Biology Technology:Golden Seeds Opens Office in PLSG Incubator 2Golden Seeds Opens Office in PLSG Incubator 3Global High Throughput Screening (HTS) Industry 2Global High Throughput Screening (HTS) Industry 3Global High Throughput Screening (HTS) Industry 4Global High Throughput Screening (HTS) Industry 5Global High Throughput Screening (HTS) Industry 6Global High Throughput Screening (HTS) Industry 7Global High Throughput Screening (HTS) Industry 8Scripps research scientists find clue to cause of childhood hydrocephalus 2Scripps research scientists find clue to cause of childhood hydrocephalus 3Scripps research scientists find clue to cause of childhood hydrocephalus 4
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) ... in the August issue of Hepatology , a ... Liver Diseases, found that metabolic syndrome significantly increases risk ... to data from the National Cancer Institute, 24,120 new ...
... , This release is available in German ... on the outer membrane for the absorption of viruses like ... well-protected against pathogenic germs. However, certain viruses, such as the ... via the mucous membrane. Just how this infiltration occurs on ...
... natural cycle that dictates our biological processes over a 24-hour ... or wake. Disruptions in the cycle are also associated with ... Prof. Yoav Gothilf of Tel Aviv University,s Department of Neurobiology ... looking to the common zebrafish to learn more about how ...
Cached Biology News:Metabolic syndrome increases risk of both major types of primary liver cancer 2Scavenger cells accomplices to viruses 2Repairing our inner clock with a 2-inch fish 2Repairing our inner clock with a 2-inch fish 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... Ion Chromatography requirements, IonQuest will ... The newly developed conductivity detector ... exceptionally ultra-low drift . The ... creates even higher sensitivities for ...
... Bionic Buffer is a unique ... and TAE (TRIS acetate-EDTA) electrophoresis buffers. ... runs, extremely rapid running times, and ... use in gel electrophoresis after dilution ...
Fujifilm Pictro-Color Process for sharp, clear reproduction comparable to silver-halide photography. Photorealistic 400 dpi quality. A4 and A5 output....
Biology Products: